Stifel Nicolaus Initiates Coverage on Sionna Therapeutics (NASDAQ:SION)

Research analysts at Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a research note issued on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $32.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 122.07% from the stock’s current price.

Separately, Guggenheim assumed coverage on Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 price target on the stock.

Sionna Therapeutics Stock Up 4.6 %

Shares of SION opened at $14.41 on Tuesday. Sionna Therapeutics has a 1-year low of $13.20 and a 1-year high of $25.19.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.